You do not have permission to access this chart.
Please Sign Up or Login

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

64

Address:

Tricida, Inc. 7000 Shoreline Court Suite 201 South San Francisco CA 94080 United States

Website:

Main page

Phone:

415-429-7800

Leave a comment

Your email address will not be published. Required fields are marked *